OVERVIEW
This 60-minute expert discussion will focus on the use of Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL), with practical considerations for the clinical application of BTK inhibitor-based therapy and a look ahead at emerging strategies from clinical trials. Expert speakers will use patient case scenarios to highlight key clinical insights and management approaches. Attendees will be able to engage directly with the panel in a live Q&A session to close the program.
GOAL STATEMENT
The goal of this activity is for learners to be better able to integrate the latest data on BTK inhibitors into clinical practice, appropriately select and sequence therapies for CLL, and optimally manage treatment-related adverse events across the treatment continuum.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[LIST][ITEM]Treatment considerations for the use of BTK inhibitors for the treatment of CLL[/LIST]Have greater competence related to[LIST][ITEM]Selecting BTK inhibitor-based therapies for the treatment of CLL[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Individualize treatment of CLL with BTK inhibitor-based therapies[/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credits[/bold][/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Fairmont Chicago Millennium Park
Gold Room - 2nd Floor
200 N Columbus Drive
Chicago, Illinois, 60601
United States
SATELLITE SYMPOSIUM ON BRUTON TYROSINE KINASE INHIBITORS IN CLL: CASE CHALLENGES AND CLINICAL INSIGHTS, FOLLOWING THE ADJOURNMENT OF THE FIRST DAY OF THE ASH MEETING ON HEMATOLOGIC MALIGNANCIES.
Supported by an independent educational grant from [bold]AstraZeneca Pharmaceuticals LP, BeiGene, Pharmacyclics LLC, An AbbVie Company, and Janssen Biotech, Inc.[/bold].